- AI-to-lab validation cycles can take six weeks
- Origin-1 handles zero-prior epitope antibody design
- Proprietary datasets continuously strengthen model training
- Candidates can advance within fourteen months
- Partnerships include major pharmaceutical companies
Absci
Generative AI antibody design with wet lab
SF7.48
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Pharma partners and biologics teams
Pharma partners and biologics teams
Best for
Pharma partners and biologics teams
Pricing
Custom
Free plan
Check vendor
SoftFinders Score
7.48 / 10
Overview
What is Absci?
Absci is a generative AI drug discovery platform for pharma and biologics teams, designing antibodies and therapeutics through integrated AI and wet-lab data.
- Research focus: It supports R&D acceleration and computational biology rather than guaranteed clinical outcomes, with candidates requiring downstream validation and trials.
- Best-fit environment: Pharma partners and biologics teams fit best when generative antibody design aligns with discovery and wet-lab workflows.
- Engagement model: Access runs through pharma partnership deals rather than self-service subscriptions, making collaboration structure, data requirements, and validated-lead timelines considerations.
- Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, with economics shaped by scope.
Absci is best assessed as a partnership-led antibody discovery platform whose fit depends on scientific objectives, wet-lab integration, and program economics.
KEY FEATURES
What you get out of the box
De novo antibody design for novel epitopes
Predicts and designs protein structures
Multi-parametric AI optimization across drug properties
Connects biological and chemical knowledge sources
Wet-lab validation of AI-generated antibody designs
Screens compound libraries against targets
Reverse immunology identifies novel therapeutic targets
Mines biomedical literature for relevant evidence
USE CASES
Where teams put it to work
Develop antibodies against difficult-to-drug therapeutic targets
Discover novel targets from immune responders
Optimize potency and developability before selection
Build half-life extension platforms for biologics
Advance oncology antibody discovery programs
Generate lead portfolios for partner programs
Editorial Take
What we like, and what to verify
- Platform primarily targets biologics and antibodies
- Platform access is partnership-led, not self-service
- Generated designs require experimental validation cycles
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.48
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.28
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.68
Why consider it
Generative protein design across modalities
Causaly SF 7.58
Why consider it
Biomedical evidence and reasoning for R&D
USER REVIEWS
Absci Reviews
Published user reviews are moderated and kept separate from the SoftFinders Score.
No published reviews yet.
Reviews from real users will appear here once published.
Used Absci?
Share your experience with other buyers.
FAQ